{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:13:49Z","timestamp":1776363229729,"version":"3.51.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Cancer Prevention&Treatment Society and Beigene"},{"name":"Beijing Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors in combination with chemotherapy have been a common first-line treatment for non-small cell lung cancer (NSCLC), but they do not work for all patients. HDAC inhibitors (HDACis) may synergize with progressive disease (PD)-1 antibodies by inducing and activating cellular immunity. In this phase II study, we assessed the efficacy and tolerability of chidamide and tislelizumab in combination with chemotherapy in NSCLC patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-arm, prospective study. Driver-gene negative locally advanced and metastatic NSCLC patients without prior systemic treatment were enrolled. Patients received chidamide, tislelizumab, and chemotherapy for 4-6 cycles and were then maintained by tislelizumab and chidamide. The primary endpoint was objective response rate (ORR), and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response, overall survival (OS) and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty patients were enrolled in the study and most of them were PD-L1 1%-49% and PD-L1 &amp;lt; 1%. At the data cutoff, ORR was 80% (95% CI, 56.3-94.3), and DCR was 100%. The median follow-up was 23.4 months, the median PFS was 11.0 months (95% CI, 9.1-12.9m), and the median OS was 17.5 months (95% CI, 9.2-25.8m). Eleven patients (55.0%) had\u2005\u2265\u2005Grade 3 treatment-related adverse events (TRAEs). The most common\u2005\u2265\u2005Grade 3 TRAEs were leukopenia (25.0%) and neutropenia (20.0%). No patients died from treatment-related adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The combination of HDACi and tislelizumab with chemotherapy showed promising antitumor effects and manageable toxicity. More studies are needed to further confirm these results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                  <jats:p>ChiCTR2000041542<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf155","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:50:24Z","timestamp":1750492224000},"source":"Crossref","is-referenced-by-count":4,"title":["First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study"],"prefix":"10.1093","volume":"30","author":[{"given":"Lijie","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-8229","authenticated-orcid":false,"given":"Ming","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical College of Nankai University, Department of Oncology , Tianjin 300071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 2nd Medical Centre of PLA General Hospital , Beijing 100036 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 1st Medical Centre of PLA General Hospital , Beijing 100036 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical College of Nankai University, Department of Oncology , Tianjin 300071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 1st Medical Centre of PLA General Hospital , Beijing 100036 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5692","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Senior Department of Oncology, 5th Medical Centre of PLA General Hospital , Beijing 100071 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025070913151129200_CIT0001","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"2025070913151129200_CIT0002","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"2025070913151129200_CIT0003","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025070913151129200_CIT0004","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025070913151129200_CIT0005","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025070913151129200_CIT0006","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025070913151129200_CIT0007","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025070913151129200_CIT0008","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025070913151129200_CIT0009","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025070913151129200_CIT0010","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol."},{"key":"2025070913151129200_CIT0011","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"2025070913151129200_CIT0012","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025070913151129200_CIT0013","doi-asserted-by":"publisher","first-page":"8797206","DOI":"10.1155\/2016\/8797206","article-title":"HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"Biomed Res Int."},{"key":"2025070913151129200_CIT0014","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025070913151129200_CIT0015","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"2025070913151129200_CIT0016","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025070913151129200_CIT0017","doi-asserted-by":"publisher","first-page":"e001696","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J ImmunoTher Cancer."},{"key":"2025070913151129200_CIT0018","doi-asserted-by":"publisher","first-page":"39003","DOI":"10.1021\/acsami.1c08290","article-title":"Combination of chidamide-mediated epigenetic modulation with immunotherapy: boosting tumor immunogenicity and response to PD-1\/PD-L1 blockade","volume":"13","author":"Tu","year":"2021","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf155\/63710061\/oyaf155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf155\/63710061\/oyaf155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T17:15:22Z","timestamp":1752081322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf155\/8195121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf155","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf155"}}